Compare Carvana Co (CVNA) vs Moderna, Inc. (MRNA) Price & Performance

Carvana (CVNA) trades at $72.01, down 2.95% today, as investors digest recent earnings and guidance. The stock shows strong technical momentum with bullish moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, CVNA delivered impressive Q2 2026 results with revenue up 52% to $7.38 billion and record retail unit growth of 38%, though full-year EBITDA guidance of $2.70–$3.0 billion disappointed some investors.

While Carvana demonstrates robust revenue growth and improving profitability, its premium valuation (P/E 38.1, EV/EBITDA 575.03) and execution risks warrant caution. The company's debt reduction from 89.99% to 41.12% debt-to-asset ratio since 2022 is positive, but competitive pressures and margin compression remain key concerns. Analyst consensus suggests 21% upside to the $87.18 price target.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.